Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil ® ): Profile Report

Author： Siddiqui M. Asif A.   Perry Caroline M.  

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.20, Iss.5, 2006-01, pp. : 313-316

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Quadrivalent Human Papillomavirus(Types 6, 11, 16, 18) Recombinant Vaccine(Gardasil®) in the Prevention of PremalignantGenital Lesions, Genital Cancer, and Genital Warts in Women†

By McCormack Paul L.  

BioDrugs, Vol. 25, Iss. 5, 2011-10 ,pp. : 339-343

Adis International

Access to resources Recommend Favorite

Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix™]: Profile Report

By Keam Susan J.  

BioDrugs, Vol. 22, Iss. 3, 2008-01 ,pp. : 205-208

Adis International

Access to resources Recommend Favorite

Spotlight on AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®)†

By McKeage Kate  

BioDrugs, Vol. 25, Iss. 4, 2011-08 ,pp. : 265-269

Adis International

Access to resources Recommend Favorite

MVA E2 Recombinant Vaccine in the Treatment of Human Papillomavirus Infection in Men Presenting Intraurethral Flat Condyloma: A Phase I/II Study

By Carvajal Antonio Albarran y.  

BioDrugs, Vol. 21, Iss. 1, 2007-01 ,pp. : 47-59

Adis International

Access to resources Recommend Favorite

In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by e6 siRNA

By Yoshinouchi M.   Yamada T.   Kizaki M.   Fen J.   Koseki T.   Ikeda Y.   Nishihara T.   Yamato K.  

Molecular Therapy, Vol. 8, Iss. 5, 2003-11 ,pp. : 762-768

Elsevier

Access to resources Recommend Favorite